BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease DrugNews DeskMay 19, 20260 A BioMarin Pharmaceutical deal last year brought the company a late-stage therapy that fit the company’s extensive enzyme replacement experience…